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Abstract  
 The present study aimed at measuring the capacity of naturally 
occurring antibodies to bind Pf83/AMA-1 and MSP-1/19 antigens, two 
malaria vaccine candidates, in an immunoassay. According to the fact that 
antibody prevalence reflects endemicity of malaria, we further aimed at 
using the results obtained here as baseline data set to follow up and evaluate 
the expected decline in endemicity in 2016, 8 years after the change in drug 
policy in Benin. Therefore, individuals, 2 – 19 and above 20 years old, living 
in Awansori, a malaria holoendemic area in the suburb of Cotonou, Benin 
were bled during the dry and raining seasons of the years 1994/1995. 
Antibody responses were measured using direct, indirect and competition 
ELISA. We found a very high prevalence of antibody responses (89 to 96%) 
in the studied population. The results indicate for Pf83/AMA-1, that 
naturally occurring antibodies bind to protective epitopes in a competition 
ELISA with a parasite inhibiting monoclonal antibody. The data and samples 
analysed here were collected during the rainy season 1994 and the following 
dry season 1994/1995.  
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 Malaria is a common infectious disease in tropical countries and 
particularly in Africa. More than half of the world population lives in the 103 
countries where malaria is endemic (Alonso, 1994, Saklatvala 1993). The 
disease is induced by the Plasmodium genus, of which many species have 
been identified, in humans: P. falciparum, Pf, P. vivax, P. ovale, P. 
malariae; with the mice: P. chabaudi P. yoeli; in rats, P. berghei, and in  
monkeys: P. Knowlesi. Among all, Pf is the most dangerous form of malaria 
in humans (Mendis, 1995). The disease control combines adequate treatment, 
vector control (Stephenson, 1991) and chemoprophylaxis in pregnant 
women. Pf has a complex cycle that brings into play two different hosts: man 
(intermediate host) and the female mosquito, anopheles (definitive host). It 
has a sexual lifecycle in the mosquito and an asexual one in humans (Deans, 
1988). Throughout its lifecycle in humans, the parasite synthesizes different 
antigenic proteins, some of which are stage specific (Stephenson, 
1991). AMA-1 and MSP-1 antigens are vaccine candidates from the Pf 
erythrocytic stage (Bouharoun- Tayoun, 1995) that are clearly immunogenic 
(GBENOUDON et al., 2016). Long-lasting antibodies against malaria in 
immigrants from several West African countries in Spain, were directed to 
AMA-1 and the 42 KD piece of MSP-1 proteins (Moncunill G et al., 2013). 
Monoclonal antibodies directed against Pf83/AMA-1 inhibited the growth of 
Pf. Thus, anti Pf83/AMA-1 antibodies play an important role in the defense 
against Pf (Terrientes 1994). 
 The current study aimed at measuring naturally induced antibodies to 
the 83 KD AMA-1 and 19 KD MSP-1 antigens in individuals living in an 
endemic area, and at testing their ability to prevent the fixation of 
monoclonal antibodies directed against protective epitopes. Furthermore, we 
aimed at measuring the prevalence of antimalarial antibodies in the study 
population in order to document the decline of malaria in that same 
population, many years after the country treatment policy has changed for 
malaria. 
 Direct, indirect and competitive ELISA allowed measuring the 
recognition of Pf83/AMA-1 and MSP-1/19 antigens, alongside with the 
ability of naturally occurring antibodies to bind to protective epitopes. The 
results showed a high prevalence (89 to 96%) of antibody response to the 
two antigens regardless of the seasons. It also indicated that anti-Pf83/AMA-
1 antibodies competed with the binding to protective Pf83/AMA-1 
epitopes. These results show the holoendemic feature of the studied area at 
the time of sample collection. Most interestingly, the results are essential set 
of data for a comparative analysis of the data that are being collected in the 
same area throughout 2016. 
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I. 
Material and methods 
 We have collected blood samples in heparin tubes from 102 
individuals (asymptomatic) living in Awansori in the outskirts of Cotonou, 
the economic capital of Benin, West Africa. The plasmas were conditioned 
with 1% azide and aliquots were stored at -80° Celsius until 
use. Parasitaemia at the time of sample collection, the spleen rate, age and 
sex, and malaria treatment were established during the samplings. 
 The antigens used came from 7G8 parasite strains, NF54 (CVD-1 
clone), and the Welcome strain of Plasmodium falciparum (Pf) cloned and 
adapted for in vitro culture. The 7G8 strain was used for the preparation of 
Pf83/AMA-l (83 KD fragment of the Pf apical membrane antigen), MSP-l/19 
(19 KD C-terminal fragment of the Pf major merozoites protein) was 
obtained from the Welcome strain (Burghaus, 1994) and total parasite 
antigens (TPA) were obtained from the CVD-1 clone of the NF54 strain 
(Thomas, 1994). 
 Different ELISA methods were used for this study. Direct ELISA 
was used to measure out the isotypes of antibodies or immunoglobulins. For 
this purpose, the total antigens were bound on the ELISA plate for the night 
and the specific antibodies contained in plasmas detected according to the 
method described by Thomas et al. (Thomas, 1994). 
 For the determination of antibodies specific to Pf83/AMA-1 and 
MSP-1 antigens, a capture ELISA was used as previously described 
(Thomas, 1994). In short, monoclonal antibodies specific to these antigens 
were first bound on the ELISA plate, then the Pf83/AMA-1 and MSP-1/19 
antigens were captured on these antibodies bound on the plate, before plasma 
addition. 
 For the competitive ELISA, it was intended to indirectly determine, if 
specific Pf83/AMA-1 antibodies contained in plasmas share the same 
epitopes as monoclonal antibodies directed against this same vaccine 
candidates, which inhibited the growth of Pf in vitro (Thomas, 1984). For 
this, the plates bound as previously described were filled either with single 
monoclonal antibodies or plasmas. Then, the plasmas-filled plates have been 
washed and filled again with monoclonal antibodies. Thus, only the 
Pf83/AMA-1 antigen sites that were not bound with the antibodies contained 
in the pre-incubated plasmas reacted with the monoclonal antibodies. The 
high-capacity binding 96-well plates (flat-bottomed microtiter ELISA plates, 
Greiner Labortechnik, Solingen, Germany) were used. 
 For the detection of specific antibodies contained in the tested 
plasma, the goat anti- human IgG antibody conjugated to alkaline 
phosphatase (Boehringer, Germany) was used, for the total IgG, and mouse 
anti human isotype antibodies, respectively, for the IgG 1, 2, 3, 4, and mouse 
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anti-human IgM (Boehringer, Germany) for IgM detection, respectively. The 
purified human IgG, IgG1-4 antibody isotypes, and the purified IgM (all 
from Sigma, Germany) served as a positive standard for each antibody to be 
detected. We also used 28G2dcl and 4G2dc1 rat monoclonal antibodies that 
respectively recognize the Pf83/AMA-1 C and N terminus. The 
measurements have been carried out in the Immunology labs at BPRC, Delft, 
Netherlands and at the Imperial College, London, England. 
  
Data analysis 
 The average value of the OD measured was obtained through the 
arithmetic mean of duplicate wells. We calculated a geometric mean, a 
standard deviation from the negative plasmas, then the ELISA Index (EI) 
using the formula as follows:  
 EI = arithmetic mean (duplicate wells of tested plasma) / [(geometric 
mean (negative controls) + 3 (Standard Deviation)] 
 The coefficient of variation (CV) is calculated for the whole test and 
as follows: CV = [standard deviation (OD negative controls) / geometric 
mean (OD negative control)] x 100 
 For the competitive inhibition ELISA, the remaining binding activity 
of the monoclonal 4G2-AP was obtained by dividing the specific OD 
(arithmetic mean) by that of the positive control (4G2-AP only). The 
inhibition percentage (% Inhibit) could then be calculated as follows: 
 % Inhibit. = 100 x (1- [(arithmetic mean OD plasma test) / 
(arithmetic mean OD positive control)] 
  
Results 
Parasitaemia in the study population 
 Individuals (n=100), divided into 5 age groups (Diagram 1) were 
taken into account in this study. The parasite rate at the time of sample 
collection was 30% in the dry season (12 830 parasites/l of blood on 
average) and 35% in the humid season (an average of 1750 parasites/l of 
blood). The parasitaemia, expressed as the number of parasites /l of blood, 
was decreasing with age. Minimum/maximum parasitaemia values were 
100/54000 and 100/14000 respectively in dry and humid seasons. 
 
Prevalence of IgG antibodies specific to Pf83/AMA-1 and MSP-1/19 
antigens 
 Both antigens gave high prevalence on average, 96% for IgG 
antibodies during the dry season. This prevalence remained during the humid 
season for Pf83/AMA-1 and with slight decrease for MSP-1/19 
(89%). Specific antibodies to total parasite antigens (TPA) were rather lower 
and prevalence rates here were constant in both seasons across the years. The 
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prevalence rate for the AMA-1 was increasing with age up to 10 years 
old. For the other age groups, the rate increased up to 100% and remains the 
same during the seasons. Such distribution was not seen for MSP-
1/19. Regarding Pf83/AMA-1 and MSP-1/19, there is a clear difference 
between the prevalence rate of the 2-4 years age group and other age groups 
(Figure 1). The lowest IgG rates were observed within the 2-4 years age 
group. These results proved that there is a good correlation between age and 
anti-AMA1 and MSP-1/19 antibody response. For MSP-1/19 however, the 
high prevalence was already observed in 2-4 years (dry season, figure 1). 
Prevalence generally increased in the subsequent age groups. 
 
 The total IgG specific to TPA, Pf83/AMA-l, and MSP-1/19 antigens 
respectively, were determined by ELISA in the indicated age groups. Plasma 
were tested at a dilution of 1/200. The total IgG bound to antigens were 
detected by the goat anti-human IgG antibody conjugated to alkaline 
phosphatase (IgG-AP) and PNPP substrate. Optical densities (OD) read at 
405 nm were then converted to ELISA index (EI) using the negative controls 
on each plate (see methods). The number of antibody-positives i.e. El ≥ 1 
was counted for each season in each age group and for the total of 100 
samples and expressed as a percentage (%).  
 
Isotypes Antibody Response 
 Of the IgG isotypes tested, IgG1 antibody against Pf83/AMA-1 
antigen was predominant in all age groups, the rate of IgG1 increased from 
2-4 years with a peak at the 15-19 years age group (Figure 2.A). For MSP-
1/19 (Figure 2.B), there was an IgM predominance in children of 2-4 years. 
For the remaining groups, IgG1 was predominant.  IgM response was also 
prevalent against total parasite antigens (TPA), Diagram 2.C 
 




IgGl, IgG2, IgG3, IgG1 to 4, and IgM Isotypes specific to A) Pf83/AMA-l, 
B) MSP-1/19, and C) TPA antigens respectively, were determined by ELISA 
in 100 (one hundred) individuals belonging to specific age groups as 
indicated. Plasma were tested at 1/200 dilution. The isotypes were detected 
by a mouse anti-human antibody, conjugated with alkaline phosphatase 
(IgG-AP), and PNPP substrate. Optical densities (OD) read at 405 nm were 
then converted to ELISA index (EI). The geometric mean of El was 
calculated for each age group as well as the corresponding standard 
deviation. Each curve represents a particular isotype. Vertical bars represent 
the standard deviation values of each group. 
 
Plasma actively competed with the monoclonal antibody (that inhibits 
the Pf growth) for binding on the antigen 
 Pf83/AMA-1 inhibition test was conducted and inhibition rates of at 
least 10% was recorded in 97% of individuals; inhibition rates of ≥50% were 
obtained in 82 and 79% of individuals, respectively for the dry and humid 
seasons. The distribution of inhibitions within age groups was the same 
across seasons. 
Table 1. Inhibition of the fixation of parasite growth inhibiting monoclonal antibody (%) per 
age group 
Age group (year) Dry season Humid season 
2-4 (n = 6) 50 50 
5-9 (n = 24) 83 83 
10-14 (n = 23) 79 79 
15-19 (n = 33) 94 88 
≥ 20 (n = 14) 71 64 
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Discussion 
IgG antibody responses directed against Pf83/AMA-1 and MSP-119 
antigens 
 We measured the specific antibodies naturally directed against 
Pf83/AMA-l and MSP-1/19 and found that 96% of surveyed individuals had 
antibodies against both antigens.  Pf83/AMA-1 and MSP-1/19 antigens were 
recognized by the plasmas of naturally exposed individuals, some of which 
were actively infected although asymptomatic (30-35% depending on the 
season). These results are consistent with those obtained in Guinea-Bissau 
and in a highly endemic region of Senegal with respect to Pf83/AMA-l 
(Peterson, 1989). IgG predominance in these regions ranged from 94 to 
100% of surveyed individuals (Riley, 1992). In two different regions of 
Gambia (West Africa), where malaria is seasonal, antibodies directed against 
MSP-1 were also found (Riley, 1992). Even nowadays antibodies against 
AMA-1 are still prevalent in endemic area, expectedly however, in much 
lower extend (Gbenoudon Satoguina et al., 2016, Moncunill et al., 2013, 
Satoguina et al., 2009; Aucan et al., 2001). In The Gambia, the prevalence 
was sometimes much lower (40%) than the one obtained in the current study 
at similar periods (Riley et al., 1992). This may be linked to the specificity of 
the area hereby surveyed where malaria transmission is perennial. 
 The prevalence of antibodies against Pf83/AMA-1 in individuals 
living in two endemic areas has also been already reported (Peterson, 
1989). Several studies also reported the antibody response directed against 
different regions of the MSP-1 protein (Egan, 1995 Riley, 1992; Terrientes 
1994, Akpogheneta OJ et al., 2007; Manz RA et al., 2005). In the present 
study we used two clearly defined purified recombinant proteins. The 
outcomes confirm that the proteins studied were immunogenic within the 
surveyed population in Benin, and help to document a period of high 
exposure to malaria at least in that area. We also had a lower prevalence rate 
regarding total parasite antigens (76%) within the surveyed population. The 
simultaneous exposure of several epitopes may have hidden from an optimal 
binding. 
 There was an age-correlation for the responses to Pf83/AMA-l and 
MSP-1/19 proteins. Regarding MSP-1/19, a threshold is not reached in the 
surveyed age groups, however concentration of antibodies directed against 
Pf83/AMA-l increased with age up to a peak between 15 and 19 years. Age 
distribution observed with MSP-1/19 is very similar to the one observed with 
the total parasite antigens. These outcomes are consistent with those obtained 
in Colombia and in The Gambia (Terrientes 1994 Riley, 1992) where the 
anti-MSP 1/19 prevalence depended on age. In Guinea, a similar result was 
obtained for distribution according to age in response to Pf83/AMA-l. In 
Senegal, Pf83/AMA-l response was not age-dependent (Peterson, 1989). In 
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endemic areas, protection against malaria is as age-dependent as are antibody 
responses so that mortality is restricted to non-immune individuals 
(Bouharoun- Tayoun, 1990, Früh 1991, Langhorne J et al., 2008). 
 Regarding the nature of the antibody isotype responses to MSP-1/19 
and Pf83/AMA-l antigens, we found that IgG1 was predominant, followed 
by IgM. However the studied plasmas were generally negative for IgG2, 
IgG3 and IgG4. The antibody isotypes involved in the humoral response 
to Pf  were evidenced by other authors who demonstrated the importance of 
the IgG1 and IgG3 isotypes in the development of protective immunity 
against malaria (Kinyanjui SM et al., 2007; Aubouy A et al., 2007). The 
study of isotypes produced in response to MSP-l /19 has been compared with 
results similar to those obtained. IgG1 was found predominant (Egan, 1995, 
Gbenoudon et al., 2016). Other studies using total parasite antigens also 
reported the predominance of IgG1 and IgG3 even in individuals subjected 
to repeated infections (Wahlgren, 1983 and 1986). Could the poor rate of 
IgG3 antibodies in our study be a particular feature of the study area? It was 
suggested that the IgG1 and IgG3 isotypes (cytophilic antibodies) would be 
predominant among pre-immune individuals while IgG2 and IgG4 (less 
cytophilic) and IgM could be present in non-immune individuals 
(Bouharoun-Tayoun, 1992). Our outcomes, with regard to IgG3, were not 
consistent with those obtained elsewhere. 
 
Inhibition of the binding of Pf83/AMA-1 specific monoclonal antibodies  
 To study the fine feature of naturally acquired antibodies directed 
against Pf83/AMA-l, the plasma of the individuals of Awansori (the study 
area), a malaria holoendemic area in Benin, were tested against a negative 
plasma for the competitive inhibition of the binding by Pf83/AMA-1 specific 
monoclonal antibody (4G2dc1) to its epitope. The 4G2dc1 monoclonal 
antibody inhibits the parasite growth in vitro. Plasma inhibition of 4G2dc1 
increased with plasma concentration thus was dose-dependent unlike 
negative plasma, which showed no inhibition. This means that there is 
competition on the monoclonal antibody binding site on the Pf83/AMA-l 
with antibodies from the plasma of individuals exposed and/or infected. We 
found that 82% of the individuals surveyed inhibited at ≥50%, the binding of 
monoclonal antibodies to Pf83/AMA-1. This indicates a certain prevalence 
of antibodies directed against similar epitopes in the studied plasma. This 
prevalence of inhibiting antibodies in the plasma, suggested that the epitope 
recognized by the monoclonal antibody and the antibodies contained in the 
plasma were very close to each other or alike. Inhibition also happened 
according to age. Similar inhibition was also reported with regard to the 
MSP-1/19 antigen (Egan, 1995). However, it should not be ruled out that the 
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presence of plasma antibodies on Pf83/AMA-l antigenic molecule might also 
have prevented the binding of the monoclonal and lead to inhibition. 
 
Conclusion 
 In conclusion, we studied the specific humoral immune response of 
MSP-1/19 and Pf83/AMA-l vaccine candidates in a group of 100 individuals 
living at Awansori, a holoendemic area in the outskirts of Cotonou in Benin. 
People were sampled during the humid and the dry seasons of 1994 and 
1995, respectively. The results showed that: 
 - there was a predominance of IgG antibody response with IgG1 
being the predominant isotype 
 - IgG and IgG1 were age-dependent 
 - The antibodies of studied plasma competitively inhibit the binding 
of the Pf83/AMA-l specific monoclonal 4G2dc1 antibody that inhibits the 
parasite growth in vitro. This suggests that the plasma recognized similar 
epitopes. 
 The present study will serve documenting the immuno-endemic 
parameters of an holoendemic area, at a time, where the malaria control 
programs were of a smaller scale, particularly regarding the use of efficient 
drugs and the nowadays widespread use of mosquito nets. On going studies, 
in 2016, in the same area will directly measure the impact of new 
antimalarial strategies by using the present study data as a baseline data set. 
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